Three Years and Seven Months Since First Patient Dosed
12.2% Dropout Rate, 95.5% Extension Study Participation

Aribio has completed dosing for the global Phase 3 clinical trial of its oral Alzheimer’s disease treatment candidate, AR1001. The large-scale trial involved 1,535 patients across 230 clinical centers in 13 countries, with the announcement of results scheduled for the second half of this year.


Aribio Completes Dosing in Global Phase 3 Trial of Oral Alzheimer’s Drug; Topline Results to Be Released in September–October View original image

On June 29, Aribio announced that the final patient has completed dosing in the global Phase 3 trial (POLARIS-AD) of its multi-mechanism oral Alzheimer’s disease treatment AR1001.


This clinical trial began in December 2022, with the first patient dosing at a clinical site in Washington State, USA. After approximately three years and seven months, the main dosing process has been completed. A total of 1,535 patients with early-stage Alzheimer’s disease were enrolled at 230 clinical centers in 13 countries including Korea, the United States, Canada, Europe, and China. Of these, 1,348 patients completed 52 weeks of dosing.


The dropout rate was recorded at 12.2%. Of the patients who completed dosing, 95.5% chose to participate in an additional one-year extension study, with more than 1,250 people expected to take part in follow-up research to collect long-term dosing data.


AR1001 is an oral small-molecule candidate for the treatment of Alzheimer’s disease. It is designed to address disease progression through multiple mechanisms, including improving cerebral blood flow, protecting neurons, and inhibiting neuroinflammation and tau protein hyperphosphorylation.


Unlike existing antibody therapies for Alzheimer’s, which are administered via injection, AR1001 is taken orally. Aribio explained that, given the chronic nature of Alzheimer’s treatment, the convenience of oral dosing could serve as a competitive advantage.


Following the completion of Phase 3 dosing, the company plans to proceed with data cleaning, database lock, and statistical analysis, and intends to release topline results—key findings—between September and October. The efficacy and safety data collected will be used as the basis for future regulatory strategies and global business expansion.


During the development of AR1001, Aribio also expanded both domestic and international business partnerships. The company has signed regional commercialization agreements with partners including Samjin Pharmaceutical and China’s Fuxing Pharmaceutical, laying the groundwork for entry into global markets.


Byunggun Lee, Special Advisor at Aribio, stated, “It is significant that we have demonstrated a model focused not only on technology out-licensing but also on direct global clinical development and commercialization. We have now entered the stage of proving value through clinical data.” Jaijoon Chung, CEO of Aribio, said, “The most important task is accurate and transparent data analysis, and we will confirm the clinical value of AR1001 with the topline results.”



Aribio is currently pursuing a merger with Kosdaq-listed company Solux. The scheduled merger date is September 29.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing